Ze-Guang Han and colleagues, at the Chinese National Human Genome Center at Shanghai, People’s Republic of China, have now identified SCARA5 as a candidate tumor suppressor gene in human hepatocellular carcinoma (HCC), a form of liver cancer that is the fifth most common cancer worldwide.
The research is reported in the Journal of Clinical Investigation.
» Read more: New Suppressor of Common Liver Cancer
Product Description
Breat cancer is the leading killer of women over 30, but its victims too often know too little about it. Brinker’s sister died of the disease ar 36 andd when Brinker herself developed breast cancer, she threw herself into research to beat the dreaded killer. She survived, and went on to found one of America’s leading cancer institution…. More >>
“Ovarian cancer is typically diagnosed at an advanced stage when it is incurable, and the same treatments have been used for virtually all patients,” says Michael Birrer, MD, PhD, director of medical gynecologic oncology in the Massachusetts General Hospital (MGH) Cancer Center, the study’s corresponding author. “Previous research from my lab indicated that different types and grades of ovarian tumors should be treated differently, and this paper now shows that even papillary serous tumors have differences that impact patient prognosis.” Birrer was with the National Institutes of Health when this study began and joined the MGH Cancer Center.
The fifth most common malignancy among U.S. women, ovarian cancer is expected to cause close to 15,000 deaths during 2009. Accounting for 60 percent of ovarian cancers, papillary serous tumors are typically diagnosed after spreading beyond the ovaries. The tumors typically return after initial treatment with surgery and chemotherapy, but while some patients die a few months after diagnosis, others may survive five years or longer while receiving treatment.
» Read more: Possible Ovarian Cancer Treatment Target Identified